Dedov I.I., Kalashnikova M.F., Belousov D.Y., Kolbin A.S., Rafalskiy V.V., Cheberda A.E., Kantemirova M.A., Zakiev V.D., Fadeyev V.V. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT- Т2DM). Sakharni Diabet = Diabetes Mellitus. 2017;20(6):403–419. (In Russ.) doi: 10.14341/DM9278.
DOI: 10.14341/DM9278
Malik R.A. Which test for diagnosing early diabetic neuropathy? Diabetes. 2014;63(7):2206–2208. doi: https://doi.org/10.2337/db14-0492..
DOI: 10.2337/db14-0492
Vinik A.I., Casellini C., Nevoret M.L. Alternative quantitative tools in the assessment of diabetic peripheral and autonomic neuropathy. Int Rev Neurobiol. 2016;127:235–285. doi: 10.1016/bs.irn.2016.03.010..
DOI: 10.1016/bs.irn.2016.03.010
Tesfaye S., Boulton A.J.M., Dyck P.J., Freeman R., Horowitz M., Kempler P. et al. Diabetic neuropathies: update on definitions, diagnostic care, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. doi: 10.2337/dc10-1303..
DOI: 10.2337/dc10-1303
Pop-Busui R., Boulton A.J.M., Feldman E.L., Bril V., Freeman R., Malik R.A., Sosenko J.M., Ziegler D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi: 10.2337/dc16-2042.
DOI: 10.2337/dc16-2042
Dyck P.J., Albers J.W., Andersen H., Arezzo J.C., Biessels G.J., Bril V. et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–628. doi: 10.1002/dmrr.1226..
DOI: 10.1002/dmrr.1226
Won J.C., Park T.S. Recent advances in diagnostic strategies for diabetic peripheral neuropathy. Endocrinol Metab. 2016;31(2):230–238. doi: 10.3803/EnM.2016.31.2.230..
DOI: 10.3803/EnM.2016.31.2.230
Rajabally Y.A. Neuropathy and impaired glucose tolerance: un updated review of the evidence. Acta Neurol Scand. 2011;124(1):1–8. doi: 10.1111/j.1600-0404.2010.01425.x..
DOI: 10.1111/j.1600-0404.2010.01425.x
Celikbilek A., Tank N., Sabah S., Borecki E., Akyol L., Ak H. et al. Elevated neurofilament light chain (NLC) mRNA levels in pre-diabetic peripheral neuropathy. Mol Biol Rep. 2014;41:4017–4022. doi: 10.1007/s11033-014-3270-y..
DOI: 10.1007/s11033-014-3270-y
Han L., Ji L., Chang J., Wen J., Zhao W., Shi H. et al. Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome. Diabetol Metab Syndr. 2015;3(7):14. doi: 10.1186/s13098-015-0010-y..
DOI: 10.1186/s13098-015-0010-y
Smith A.G., Rose K., Singleton J.R. Idiopathic neuropathy patients are at high risk for metabolic syndrome. J Neurol Sci. 2008;273(1–2):25–28. doi: 10.1016/j.jns.2008.06.005..
DOI: 10.1016/j.jns.2008.06.005
Spijkerman A.M., Dekker J.M., Nijpels G. et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care. 2003;26(9):2604–2608. doi: 10.2337/diacare.26.9.2604..
DOI: 10.2337/diacare.26.9.2604
England J.D., Gronseth G.S., Franklin G., Miller R.G., Asbury A.K., Carter G.T. et al. Distal symmetric polyneuropathy: a definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic medicine, and the American Academy of Physical medicine and Rehabilitation. Neurology 2005;64(2):199–207. doi: 10.1212/01.WNL.0000149522.32823.EA..
DOI: 10.1212/01.WNL.0000149522.32823.EA
American Diabetes Association. Standards of Medical Care in Diabetes. Microvascular complications and foot care. Diabetes Care. 2017;40(1):88–98. doi: 10.2337/dc17-S013..
DOI: 10.2337/dc17-S013
Alam U. Prevalence of Peripheral Neuropathy in Prediabetes. Diabetes. 2018;67(Suppl. 1):552-P. doi: 10.2337/db18-552-P..
DOI: 10.2337/db18-552-P
Lee C.C., Perkins B.A., Kayaniyil S., Harris S.B., Retnakaran R., Gerstein H.C., Zinman B., Hanley A.J. Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015;38(50):793–800. doi: 10.2337/dc14-2585..
DOI: 10.2337/dc14-2585
Dyck P.J. Detection, characterization and staging of polyneuropathy: assessed in diabetics. Muscle Nerve. 1988;11(1):21–32. doi: 10.1002/mus.880110106..
DOI: 10.1002/mus.880110106
Russell J.W., Zilliox L.A. Diabetic Neuropathies. Continuum (Minneap Minn). 2014;20(5):1226–140. doi: 10.1212/01.CON.0000455884.29545.d2..
DOI: 10.1212/01.CON.0000455884.29545.d2
Feng Y., Schossler P.J., Sumpio B.E. The Semmes-Weinstein monofi lament is a signifi cant predictor of the risk of foot ulceration and amputation in patients with diabetes mellitus. J Vasc Surg 2011;53(1):220–226. doi: 10.1016/j.jvs.2010.06.100..
DOI: 10.1016/j.jvs.2010.06.100
Bril V., Perkins B., Toth C. Canadian Diabetes Association Clinical Practice Guidelines. Neuropathy. Can J Diabetes. 2013;37(1):142–144. doi: 10.1016/j.jcjd.2013.01.039..
DOI: 10.1016/j.jcjd.2013.01.039
Dros J., Wewerinke A., Bindels P.J., von Weert H.C. Accuracy of monofilament testing to diagnose peripheral neuropathy: a systematic review. Ann Fam Med. 2009;7(6):555–558. doi: 10.1370/afm.1016..
DOI: 10.1370/afm.1016
Feldman E.L., Stevens M.J., Thomas P.K., Brown M.B., Canal M., Greene D.A. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281–1289. doi: 10.2337/diacare.17.11.1281..
DOI: 10.2337/diacare.17.11.1281
Herman W.H., Pop-Busui R., Braffett B.H., Martin C.L., Cleary P.A., Albers J.W., Feldman E.L.; DCCT/EDIC Research Group. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012;29(7):937–944. doi: 10.1111/j.1464-5491.2012.03644.x..
DOI: 10.1111/j.1464-5491.2012.03644.x
Moghtaderi A., Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006;108(5):477–481. doi: 10.1016/j.clineuro.2005.08.003..
DOI: 10.1016/j.clineuro.2005.08.003
Singleton J.R., Bixby B., Russell J.W., Feldman E.L., Peltier A., Goldstein J., Howard J., Smith A.G. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Periph Nerv Syst. 2008;13(3):218–227. doi: 1111/j.1529-8027.2008.00180.x..
DOI: 1111/j.1529-8027.2008.00180.x
Vinik E., Hayes R.P., Oglesby A., Bastyr E., Barlow P., Ford-Molvik S.L., Vinik A.I. The development and validation of the Norfolk QOL-DN, a new measure of patients´ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2008;7(3):497–508. doi: 10.1089/dia.2005.7.497..
DOI: 10.1089/dia.2005.7.497
Hillienmark L., Alstrand N., Jonsson B., Ludvigson J., Cooray G., Wahlberg- Topp J. Early electrophysiological abnormalities and clinical neuropathy. Diabetes Care. 2013;36(10):3187–3194. doi: 10.2337/dc12-2226..
DOI: 10.2337/dc12-2226
Shin J.B., Seong Y.J., Lee H.J., Kim S.H., Suk H., Lee Y.J. The usefulness of minimal F-wave latency and sural/radial amplitude ratio in diabetic polyneuropathy. Yonsei Med J. 2000;41(3):393–397. doi: 10.3349/ymj.2000.41.3.393..
DOI: 10.3349/ymj.2000.41.3.393
Dyck P.J., Litchy W., Daube J.R., Harper M., Dyck J.B., Davies J., O’Brien P.C. Individual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility and concordance with impairment. Muscle Nerve 2003;27(2):202–210. doi: 10.1002/mus.10320..
DOI: 10.1002/mus.10320
Albers J.W., Brown M.B., Sima A.A.F., Greene D.A. Frequency of median nerve mononeuropathy in patients with mild diabetic polyneuropathy in the early diabetes intervention trial (EDIT). Muscle Nerve;1996;19(2):140–146. doi: 10.1002/(SICI)1097-4598(199602)19:2<140::AID-MUS3>3.0.CO;2-E..
DOI: 10.1002/(SICI)1097-4598(199602)19:2<140::AID-MUS3>3.0.CO;2-E
Horinouchi S., Deguchi T., Arimura K., Arimura A., Dochi Y., Uto T. et al. Median neuropathy at the wrist as an early manifestation of diabetic neuropathy. J Diabetes Invest. 2014:5(6):709–713. doi: 10.5455/medarh.2014.68.98-101..
DOI: 10.5455/medarh.2014.68.98-101
Sung J.-Y., Tani J., Chang T.-S., Lin C.S.-Y. Uncovering sensory axonal dysfunction in asymptomatic type 2 diabetic neuropathy. PLoS ONE. 2017;12(2):e0171223. doi: 10.1371/journal.pone.0171223..
DOI: 10.1371/journal.pone.0171223
Van der Heyden J.C., van der Meer P., Birnie E., de Coo F.M. et al. Decreased excitability of the distal motor nerve of young patients with type-1 diabetes mellitus. Pediatr Diabetes. 2013;14(7):519–525. doi: 10.1111/pedi.12048..
DOI: 10.1111/pedi.12048
American Diabetes Association, American Academy of Neurology. Report and recommendations of the San Antonio Conference on Diabetic neuropathy. Diabetes Care. 1988;11(7):592–597. doi: 10.2337/diacare.11.7.592..
DOI: 10.2337/diacare.11.7.592
Andresen H., Stalberg E., Falck B. F-wave latency, the most sensitive nerve conduction parameter in patients with diabetes mellitus. Muscle Nerve. 1997;20(10):1296–1302. doi: 10.1002/(SICI)1097-4598(199710)20:10<1296::AIDMUS12>3.0.CO;2-1..
DOI: 10.1002/(SICI)1097-4598(199710)20:10<1296::AIDMUS12>3.0.CO;2-1
Kohara N., Kimura J., Kaji R., Goyo Y., Ishii J., Takiguchi M., Nakai M. F-wave latency serves as the most reproductible measure in nerve conduction studies of diabetic polyneuropathy: multicenter analysis in healthy patients and patients with diabetic polyneuropathy. Diabetologia 2000;43:915–921. doi: 10.1007/s001250051469..
DOI: 10.1007/s001250051469
Pan H., Jian F., Lin J., Chen N., Zhang C., Zhang Z. et al. F-wave latencies in patients with diabetes mellitus. Muscle Nerve. 2014;49(6):804–808. doi: 10.1002/mus.24127..
DOI: 10.1002/mus.24127
Lachman T., Shahani B.T., Young R.R. Late responses as aids to diagnosis in peripheral neuropathies. J Neurol Neurosurg Psychiatry. 1980;43:156–162. doi: 10.1136/jnnp.43.2.156..
DOI: 10.1136/jnnp.43.2.156
Toopchizadeh V., Shiva S., Khiabani N.Y., Ghergherechi R. Electrophysiologic pattern and prevalence of subclinical peripheral neuropathy in children and adolescents with type-1 diabetes mellitus in Iran. Saudi Med J. 2016;37(3):299–303. Available at: https://www.pubfacts.com/detail/26905353/Electrophysiologic-pattern-and-prevalence-ofsubclinical-peripheral-neuropathy-in-children-and-adole.https://www.pubfacts.com/detail/26905353/Electrophysiologic-pattern-and-prevalence-ofsubclinical-peripheral-neuropathy-in-children-and-adole
Pozzessere G., Rossi P., Gabriele A., Cipriani R., Morocutti A., Di Mario U., Morano S. Early detection of small fiber neuropathy in Diabetes. Diabetes Care. 2000;25(12):2355–2357. doi: 10.2337/diacare.25.12.2355..
DOI: 10.2337/diacare.25.12.2355
Sumner C.J., Sheth S., Griffin J.W., Cornblath D.R., Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60(1):108–111. doi: 10.1212/wnl.60.1.108..
DOI: 10.1212/wnl.60.1.108
Yaman M., Uluduz D., Yuksel S., Pay G., Kiziltan M.E. The cutaneous silent period in diabetes mellitus. Neurosci Lett. 2007;419(3):258–262. doi: 10.1016/j.neulet.2007.04.018..
DOI: 10.1016/j.neulet.2007.04.018
Shy M.E., Frohman E.M., So Y.T., Arezzo J.C., Cornblath D.R., Giuliani M.J. et al. Quantitative sensory testing. Report of the therapeutics and technology assessment subcomitee of the American Academy of Neurology. Neurology. 2003;60(6):898–904. doi: 10.1212/01.wnl.0000058546.16985.11..
DOI: 10.1212/01.wnl.0000058546.16985.11
Tavakoli M., Petroupoulos I.N., Malik R.A. Corneal confocal microscopy to assess diabetic neuropathy. J Diabetes Sci Technol. 2013;7(5):1179–1189. doi: 10.1177/193229681300700509..
DOI: 10.1177/193229681300700509
Merita Tiric-Campara, Miro Denislic, Jasminka Djelilovic-Vranic, Azra Alajbegovic, Emir Tupkovic, Refet Gojak, Rok Zorec, Jasem Y. Al-Hashel. Cutaneous Silent Period in the Evaluation of Small Nerve Fibres. Med Arh. 2014 Apr; 68(2):98-101. doi: 10.5455/medarh.2014.68.98-101.
DOI: 10.5455/medarh.2014.68.98-101
Švilpauskaitė J., Truffert A., Vaičienė N., Magistris M.R. Electrophysiology of small peripheral nerve fibers in man. A study using the cutaneous silent period. Medicina (Kaunas). 2006;42(4):300–312. Available at: http://medicina.lsmuni.lt/med/0604/0604-06e.pdf.http://medicina.lsmuni.lt/med/0604/0604-06e.pdf
Koytac P.K., Isak B., Borucu D., Uluk K. Assessment of symptomatic diabetic patients with normal nerve conduction studies: utility of cutaneous silent period and autonomic tests. Muscle Nerve. 2011;43(3):317–323. doi: 10.1002/mus.21877..
DOI: 10.1002/mus.21877
Onal M.R., Ulas U.H., Oz O., Bek V.S., Yucel M., Talispinar A., Odabası Z. Cutaneous silent period changes in type-2 diabetes mellitus patients with small fiber neuropathy. Clin Neurophysiol. 2010;121(5):714–718. doi: 10.1016/j.clinph.2009.12.024..
DOI: 10.1016/j.clinph.2009.12.024
Braune H.J., Horter C. Sympathetic skin responses in diabetic neuropathy: a prospective clinical and neurophysiological trial on 100 patients. J Neurol Sci. 1996;138(1–2):120–124. doi: 10.1016/0022-510x(96)00023-8..
DOI: 10.1016/0022-510x(96)00023-8
Isak B., Oflazoglu B., Tanridag T., Yitmen I., Us O. Evaluation of peripheral and autonomic neuropathy among patients with newly diagnosed impaired glucose tolerance. Diabetes Metab Res Rev. 2008;24(7):563–569. doi: 10.1002/dmrr.859..
DOI: 10.1002/dmrr.859
Casellini C.M., Parson H.K., Richardson M.S., Nevoret M.L., Vinik A.I. SUDOSCAN, a non-invasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther. 2013;15(11):948–953. doi: 10.1089/dia.2013.0129..
DOI: 10.1089/dia.2013.0129
Mao F., Liu S., Qiao X., Zheng H., Xiong Q., Wen J. et al. Sudoscan is an effective screening method for asymptomatic diabetic neuropathy in chinese type-2 diabetes mellitus patients. J Diabetes Investig. 2017;8(3):363–368. doi: 10.1111/jdi.12575..
DOI: 10.1111/jdi.12575
Mayaudon H., Miloche P.O., Bauduceau B. A new simple method for assessing sudomotor function: Relevance in type-2 diabetes. Diabetes Metab. 2010;(6 Pt 1):450–454. doi: 10.1016/j.diabet.2010.05.004..
DOI: 10.1016/j.diabet.2010.05.004
Selvarajah D., Cash T., Davies J., Sankar A., Rao G., Grieg M. et al. SUDOSCAN: A simple, rapid and objective method with potential for screening for diabetic peripheral neuropathy. PloS ONE. 2015;10(10):e0138224. doi: 10.1371/journal.pone.0138224..
DOI: 10.1371/journal.pone.0138224
Smith A.G., Lessard M., Singleton J.R. The diagnostic utility of SUDOSCAN for distal symmetric peripheral neuropathy. J Diabetes Complications. 2014;28(4):511–516. doi: 10.1016/j.jdiacomp.2014.02.013..
DOI: 10.1016/j.jdiacomp.2014.02.013
Yajnik C.S., Kantikar V.V., Pande A.J., Deslypere J.P. Quick and simple evaluation of sudomotor function for screening of diabetic neuropathy. ISRN Endocrinol. 2012;2012:103714. doi: 10.5402/2012/103714..
DOI: 10.5402/2012/103714
Papanas N., Papatheodorou K., Papazoglou D., Christakidis D., Monastiriotis C., Maltezos E. The new indicator test: a valuable diagnostic tool for small fiber impairment in patients with type-2 diabetes. Diabetes Educ. 2007;33(2):251–258. doi: 10.1177/0145721707299661.
DOI: 10.1177/0145721707299661
Shimada H., Kihara M., Kosaka S., Ikeda H., Kawabata K., Tsutada T., Miki T. Comparison of SSR and QSART in early diabetic neuropathy – the value of length-dependent pattern in QSART. Auton Neurosci. 2001;92(1–2):72–75. doi: 10.1016/S1566-0702(01)00287-9..
DOI: 10.1016/S1566-0702(01)00287-9
Sommer P., Kluschina O., Scley M., Namer B., Schmelz M., Rukwied R. Electrically induced quantitative sudomotor axon test in human volunteers. Auton Neurosci. 2011;159(1–2):111–116. doi: 10.1016/j.autneu.2010.09.004..
DOI: 10.1016/j.autneu.2010.09.004
Ravits J.M. AAEM minimonograph #48: autonomic nervous system testing. Muscle Nerve. 1997;20(8):919–937. doi: 10.1002/(sici)1097-4598(199708)20:8<919::aid-mus1>3.0.co;2-9..
DOI: 10.1002/(sici)1097-4598(199708)20:8<919::aid-mus1>3.0.co;2-9
Guthoff R.F., Zhivov A., Stachs O. In vivo confocal microscopy, an inner vision of the cornea – a major review. Clin Expermient Ophtalmol. 2009;37(1):100–117. doi: 10.1111/j.1442-9071.2009.02016.x..
DOI: 10.1111/j.1442-9071.2009.02016.x
Azmi S., Ferdousi M., Petropoulos I.N., Ponirakis G., Alam U., Fadavi H. et al. Corneal comnfocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type-2 diabetes. Diabetes Care. 2015;38(8):1502–1508. doi: 10.2337/dc14-2733..
DOI: 10.2337/dc14-2733
Lauria G., Lombardi R., Camozzi F., Devigli G. Skin biopsy for the diagnosis of peripheral neuropathy. Histopathology. 2009;54(3):273–285. doi: 10.1111/j.1365-2559.2008.03096.x..
DOI: 10.1111/j.1365-2559.2008.03096.x
Sommer C., Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet Neurol. 2007;6(7):632–642. doi: 10.1016/S1474-4422(07)70172-2..
DOI: 10.1016/S1474-4422(07)70172-2
Periquet M.J., Novak V., Collins M.P., Nagaraja H.N., Erdem S., Nash S.M. et al. Painful sensory neuropathy. Prospective evaluation using skin biopsy. Neurology. 1999;53(8):1641–1647. doi: 10.1212/wnl.53.8.1641..
DOI: 10.1212/wnl.53.8.1641
Saperstein D.S., Levine T.D. Diagnosing small fiber neuropathy through the use of skin biopsy. Pract Neurol. 2009;8:37–40. Available at: https://corinthianreferencelab.com/wp-content/uploads/2018/01/Pract_Neuro.pdf.https://corinthianreferencelab.com/wp-content/uploads/2018/01/Pract_Neuro.pdf
Herder C., Roden M., Ziegler D. Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. Trends in Endocrinology and Metabolism. 2019;30(5):286–298. doi: 10.1016/j.tem.2019.02.007..
DOI: 10.1016/j.tem.2019.02.007
Zoppini G., Cacciatori V., Raimondo D., Gemma M., Trombetta M., Dauriz M. et al. The prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type-2 diabetes. The Verona Newly Diagnosed Type-2 Diabetes Study (VNDS). Diabetes Care. 2015;38(8):1487–1493. doi: 10.2337/dc15-0081..
DOI: 10.2337/dc15-0081
Rolim L.C., Sa J.R., Chacra A.R., Dib S.A. Diabetic cardiovascular autonomic neuropathy: risk factors, clinical impact and early diagnosis. Arq Bras Cardiol. 2008;90(4):e24–31. doi: 10.1590/s0066-782x2008000400014..
DOI: 10.1590/s0066-782x2008000400014
Zilliox L., Peltier A.C., Wren P.A., Anderson A., Smith A.G., Singleton J.R. et al. Assessing autonomioc dysfunction in the early diabetic neuropathy. The Survey of Autonomic Symptom. Neurology. 2011;76(12):1099–1105. doi: 10.1212/WNL.0b013e3182120147..
DOI: 10.1212/WNL.0b013e3182120147
Ishibashi F., Taniguchi M., Kojima R., Awasaki A., Kosaka A., Uetake H. Elasticity of the tibial nerve assessed by sonoelastography was reduced before the development of neuropathy and further deterioration associated with the severity of neuropathy un type-2 diabetes. J Diabetes Investig. 2016;7(3):404–412. doi: 10.1111/jdi.12408..
DOI: 10.1111/jdi.12408
Pitarokopilli K., Kerasnoudis A., Behredt V., Labedi A., Ayzenberg I., Gold R., Yoon M.-S. Facing the diagnostic challenge: Nerve Ultrasound in diabetic patients with neuropathic symptoms. Muscle Nerve. 2016;54(1):18–24. doi: 10.1002/mus.24981..
DOI: 10.1002/mus.24981
Vaeggemose M., Ringgaard S., Ejskjaer N., Andersen H. Magnetic Resonance Imaging may be used for early evaluation of diabetic peripheral neuropathy. J Diabetes Sci Technol. 2015;9(1):162–163. doi: 10.1177/1932296814559303..
DOI: 10.1177/1932296814559303
Pham M., Oikonomou D., Hornung B., Weiler M., Heiland S., Baumer P. et al. Magnetic resonance neurography detects diabetic neuropathy early and with proximal predominance. Ann Neurol. 2015;78(6):939–948. doi: 10.1002/ana.24524..
DOI: 10.1002/ana.24524
Choi A., Kim H.W., Kwon J.W., Shim Y.S., Jee D.H., Yun J.S. et al. Early inner retinal thinning and cardiovascular autonomic dysfunction in type-2 diabetes. PloS ONE. 2017;12(3):e0174377. doi: 10.1371/journal.pone.0174377..
DOI: 10.1371/journal.pone.0174377
Akbar M., Bhandari U., Habib A., Ahmad R. Potential association of triglyceride glucose index with cardiac autonomic neuropathy in type-2 diabetes mellitus patients. J Korean Sci. 2017;32(7):1131–1138. doi: 10.3346/jkms.2017.32.7.1131..
DOI: 10.3346/jkms.2017.32.7.1131
Scott L.A., Kench P.L. Cardiac autonomic neuropathy in the diabetic patient. Does 123I-MIBG imaging have a role to play in early diagnosis? Nucl Med Technol. 2004;32(2):66–71. Available at: http://tech.snmjournals.org/content/32/2/66.http://tech.snmjournals.org/content/32/2/66
Hattori N., Tamaki N., Hayashi T., Masuda I., Kudoh T., Tateno M. et al. Regional abnormality of Iodine-123-MIBG in diabetic hearts. J Nucl Med. 1996;37(12):1985–1990. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8970519.https://www.ncbi.nlm.nih.gov/pubmed/8970519
Schnell O., Hammer K., Muhr-Becker D., Ziegler AG, Weiss M., Tatsch K., Standl E. Cardiac sympathetic dysinnervation in type-2 diabetes mellitus with and without ECG-based cardiac autonomic neuropathy. J Diabetes Complications. 2006;16(3):220–227. doi: 10.1016/s1056-8727(01)00180-5..
DOI: 10.1016/s1056-8727(01)00180-5
Scholte A.J.H.A., Schvijf J.D., Delgado V., Kok J.A., Bus M.T.J., Maan A.C. et al. Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability. Eur J Nucl Med Mol Imaging. 2010;37:1698–1705. doi: 10.1007/s00259-010-1442-0..
DOI: 10.1007/s00259-010-1442-0
Shakher J., Stevens M.J. Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes.2011;4:289–305. doi: 10.2147/DMSO.S11324..
DOI: 10.2147/DMSO.S11324
The Diabetes Control and Complications Trial research group: the effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122(8):561–568. doi: 10.7326/0003-4819-122-8-199504150-00001..
DOI: 10.7326/0003-4819-122-8-199504150-00001
Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A.C. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;(6):CD007543. doi: 10.1002/14651858.CD007543.pub2..
DOI: 10.1002/14651858.CD007543.pub2
Zhoungas S., Arima H., Gerstein H.C., Holman R.R., Woodward M., Reaven P. et al. Effect of intensive glucose control on microvascular outcomes in patients with type-2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–437. doi: 10.1016/S2213-8587(17)30104-3..
DOI: 10.1016/S2213-8587(17)30104-3
Stino A.M., Smith A.G. Peripheral neuropathy in the prediabetes and the metabolic syndrome. J Diabetes Investig. 2017;8(5):646–655. doi: 10.1111/jdi.12650. 86. Smith A.G., Russell J., Feldman E.L., Goldstein J., Peltier A. et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294–1299. doi: 10.2337/dc06-0224..
DOI: 10.2337/dc06-0224
Singleton J.R., Marcus R.L., Jackson J.E., Lessard M.K., Graham T.E., Smith A.G. Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Trans Neurol. 2014;1(10):844–849. doi: 10.1002/acn3.125..
DOI: 10.1002/acn3.125
Singleton J.R., Marcus R.L., Lessard M., Jackson J.E., Gordon Smith A. Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients. Ann Neurol. 2015;77(1):146–153. doi: 10.1002/ana.24310..
DOI: 10.1002/ana.24310
Khang S.J., Ko K.J., Baek U.H. Effect of 12 weeks combined aerobic and resistance exercise on heart-rate variability in type-2 diabetes mellitus patients. J Phys Ther Sci. 2016;28(7):2088–2093. doi: 10.1589/jpts.28.2088..
DOI: 10.1589/jpts.28.2088
Pennathur S., Jaiswal M., White E.A., Ang L., Raffel D.M., Rubenfire M., Pop- Busui R. Structured lifestyle intervention in patients with the metabolic syndrome mitigates oxidative stress but fails to improve measures of cardiovascular autonomic neuropathy. J Diabet Compl. 2017;31(9):1437–1443. doi: 10.1016/j.jdiacomp.2017.03.008..
DOI: 10.1016/j.jdiacomp.2017.03.008
Golbidi S., Badran M., Laher I. Diabetes and alpha lipoic acid. Front Pharmacol. 2011;2:69. doi: 10.3389/fphar.2011.00069..
DOI: 10.3389/fphar.2011.00069
Manning P.J., Sutherland W.H.F., Williams S.M., Walker R.J., Berry E.A., De Jong S.A., Ryalls A.R. The effect of lipoic acid and the vitamin E therapies in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2013;23(6):543–549. doi: 10.1016/j.numecd.2011.11.006..
DOI: 10.1016/j.numecd.2011.11.006
Namazi N., Larijani B., Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Clin Nutr. 2018;37(2):419–428. doi: 10.1016/j.clnu.2017.06.002..
DOI: 10.1016/j.clnu.2017.06.002
Sun H., Yao W., Tang Y., Zhuang W., Wu D., Huang S., Sheng H. Urinary exosomes as a novel biomarker for the evaluation of a-lipoic acid´s protective effect in early diabetic nephropathy. J Clin Lab Anal. 2017;31(6):e22129. doi: 10.1002/jcla.22129..
DOI: 10.1002/jcla.22129
Han T., Bai J., Liu W., Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012;167(4):465–471. doi: 10.1530/EJE-12-0555..
DOI: 10.1530/EJE-12-0555
Mijnhout G.S., Kollen B.J., Alkhalaf A., Kleefstra N., Bilo H.J. Alpha Lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a metaanalysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279. doi: 10.1155/2012/456279..
DOI: 10.1155/2012/456279
Tankova T., Koev D., Dakovska L. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). Rom J Intern Med. 2004;42(2):457–464. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15529636.https://www.ncbi.nlm.nih.gov/pubmed/15529636
Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A. et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. Diabetes Care. 2006;29(11):2365–2370. doi: 10.2337/dc06-1216..
DOI: 10.2337/dc06-1216
Ziegler D,, Schatz H,, Conrad F,, Gries F,A,, Ulrich H,, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicentre trial (DEKAN Study). Diabetes Care. 1997;20(3);369–373. doi: 10.2337/diacare.20.3.369..
DOI: 10.2337/diacare.20.3.369
Grewal A.S., Bhardwaj S., Pandita D., Lather V., Sekhon B.S. Updates on Aldose Reductase Inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem. 2016;16(2):120–162. doi: 10.2174/1389557515666150909143737..
DOI: 10.2174/1389557515666150909143737
Stacke H., Gaus W., Achenbach U., Federlin K., Bretzel R.G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised doubleblind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600–605. doi: 10.1055/s-2008-1065351..
DOI: 10.1055/s-2008-1065351
Won J.C., Kwon H.S., Moon S.S., Chun S.W., Kim C.H. et al. γ-Linolenic Acid versus α-Lipoic Acid for Treating Painful Diabetic Neuropathy in Adults: A 12-Week, Double-Placebo, Randomized, Noninferiority Trial. Diabetes Metab J. 2019;43:e60. doi: 10.4093/dmj.2019.0099..
DOI: 10.4093/dmj.2019.0099
Keen H., Payan J., Allawi J. et al. Treatment of Diabetic Neuropathy With γ-Linolenic Acid. Diabetes Care 1993;16(1):8–15. doi: 10.2337/diacare.16.1.8..
DOI: 10.2337/diacare.16.1.8
Rolim L.C., da Silva E.M.K., Flumignan R.L.G., Abreu M.M., Dib S.A. Acetyl- L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews. 2019;(6):CD011265. doi: 10.1002/14651858.CD011265.pub2..
DOI: 10.1002/14651858.CD011265.pub2
Ziegler D., Movsesyan L., Mankovsky B., Gurieva I., Abylaiuly Zh., Strokov I. Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients. Diabetes Care. 2009;32(8):1479–1484. doi: 10.2337/dc09-0545..
DOI: 10.2337/dc09-0545